Orchid Pharma Limited has entered into a licensing and supply agreement with Pharmasyntez JSC, Russia, to commercialise Exblifep (cefepime/enmetazobactam) in the Russian market, as per the exchange filings.
The agreement is subject to approval from the Ministry of Health of the Russian Federation and represents a potential $178 million opportunity over the first 10 years.
Under the agreement, Pharmasyntez will receive exclusive rights to register and commercialise Exblifep in Russia, while Orchid Pharma will manufacture and supply the finished dosage form.
The opportunity is supported by significant unmet clinical demand and large hospital procurement volumes in the country.
Exblifep is a carbapenem-sparing combination antibiotic developed to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens.
The medicine has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
It is also included in IDSA and EUCAST treatment guidelines, becoming the first New Chemical Entity originating from an Indian pharmaceutical company to secure approvals from both regulators.
Commenting on the agreement, Managing Director Manish Dhanuka said, "Our partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia." He added that Pharmasyntez's strong presence in Russia's hospital procurement system would help expand patient access.
Natalia Malykh, Vice President of Business Development at the Pharmasyntez Group, said the agreement would enable Russian patients to gain access to modern antibacterial therapy.
Read More: Cupid Share Price Surges Nearly 60% in 1 Month; Company Raises FY27 Revenue Guidance!
As of 08 July 2026, at 12:30 PM, Orchid Pharma Ltd share price was trading at ₹1,018 per share, reflecting a surge of 10.13% from the previous trading session.
The licensing and supply agreement gives Orchid Pharma an opportunity to expand Exblifep into the Russian market through an exclusive commercialisation partnership with Pharmasyntez. The collaboration carries a potential value of $178 million over the first decade, subject to regulatory approval.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 8, 2026, 2:48 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
